Oncopeptides Announces Rights Issue

Oncopeptides executes a rights issue of approx SEK 200 million. Proceeds will support Pepaxti commercialization in Europe and advance the glioblastoma project to clinical development, including a window-of-opportunity study. HealthCap VIII LP commits SEK 20 million.

#biotech #lifescience #stockmarket #Oncopeptides